Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ADK | P55263 | 9/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | ABL2 | P42684 | 4/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | NPM1 | P06748 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951321 | 1.00 | SRC (0.53) | SRCMTORRAB9AADKRIPK2 | |
| SCHEMBL16237288 | 0.89 | SRC (0.59) | SRCMTORRAB9AADKRIPK2 | |
| SCHEMBL400703 | 0.88 | SRC (0.59) | SRCMTORRAB9AADKABL1 | |
| SCHEMBL397335 | 0.88 | SRC (0.59) | SRCMTORRAB9AADKABL1 | |
| SCHEMBL397336 | 0.88 | SRC (0.59) | SRCMTORRAB9AADKABL1 | |
| SCHEMBL9950846 | 0.85 | ADK (0.62) | SRCMTORRAB9AADKRIPK2 | |
| SCHEMBL9950847 | 0.85 | ADK (0.62) | SRCMTORRAB9AADKRIPK2 | |
| SCHEMBL9951080 | 0.85 | ADK (0.56) | SRCMTORRAB9AADKRIPK2 | |
| SCHEMBL1442815 | 0.85 | ADK (0.56) | SRCMTORRAB9AADKRIPK2 | |
| SCHEMBL1933267 | 0.84 | RIPK2 (0.63) | SRCMTORRAB9AADKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475668-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011029915-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | SRC 292/4885MTOR 1267/4885RAB9A 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.